Telisotuzumab medical insurance reimbursement policy and specific details

Telisotuzumab (Telisotuzumab Vedotin) is an antibody drug conjugate (ADC) targeting the c-Met protein. It is mainly used to treat patients with high expression of c-Met in non-small cell lung cancer (NSCLC). According to information on the accelerated approval of the US FDA in 2025, the drug can be used to treat tumors that have been previously treated and have strong c-Met expression (IHC 3+) advanced non-squamous NSCLCpatients. It has been used clinically abroad, but it has not yet been officially launched in China and is not covered by medical insurance policies.

As far as the Chinese market is concerned, as of now (2025year8month), terituzumab has not yet received marketing approval from the National Medical Products Administration (NMPA), and therefore has not been included in China's medical insurance directory. This means that domestic patients cannot use the drug through medical insurance reimbursement, and it cannot be purchased directly in domestic hospitals or pharmacies for the time being. If patients need it, they usually need to purchase drugs overseas or participate in international multi-center clinical trials.

As for whether it will be included in medical insurance in the future, we still need to wait for the registration process of the drug in China and the price negotiation after it is launched. According to the previous process of similar targeted drugs, if terituzumab is approved for marketing in China in the future and an application for medical insurance negotiation is submitted, the medical insurance department will comprehensively evaluate whether to include it in the reimbursement catalog based on its clinical value, treatment population, international price level and cost-effectiveness ratio, and may only open medical insurance qualifications to patients who test positive for specific genes.

In general, terituzumab is currently not on the market in China, nor has it been included in the medical insurance catalog. Patients need to seek overseas channels if they need the drug. While waiting for approval, patients are advised to evaluate whether they are eligible for clinical trial enrollment under the guidance of a professional physician or consider other approved alternative treatment options. At the same time, we should also pay close attention to the subsequent development of China's marketing approval and the results of medical insurance negotiations, so as to benefit as soon as possible after the drug officially enters the market.

Reference materials:https://www.drugs.com/